NCT07332260 Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study
| NCT ID | NCT07332260 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University Hospital of North Norway |
| Condition | Alzheimer s Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-05 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2026-05 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.
Eligibility Criteria
Inclusion Criteria: * Alzheimer's dementia mild to moderate stage * Presence of Alzheimer pathology core 1 biomarkers as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (2024) * Capable of giving informed consent Exclusion Criteria: * Contraindications for colonoscopy examination * Contraindications for Magnetic Resonance Imaging (MRI) * Life expectancy \< 1 year * Clinical frailty scale 7 or more * History of seizure disorder * History of brain tumour or intracranial bleed * Major psychiatric disorder such as schizophrenia, bipolar disorder, or major depressive disorder * Alcohol or substance abuse * Decompensated heart disease * Malignancy * Current use of anticoagulant treatment (dual acting oral anticoagulant or warfarin) * Pregnant or planning pregnancy * Colonic adenomas over 1 cm, tumours or signs of active colitis on colonoscopy * Status after colectomy or hemicolectomy * Inflammatory bowel disease * Immunocompromised individual * Receiving biological/antibody treatment
Contact & Investigator
Mona Dixon Gundersen, MBChB, PhD
PRINCIPAL INVESTIGATOR
University Hospital of North Norway, Tromsø
Frequently Asked Questions
Who can join the NCT07332260 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07332260 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07332260 currently recruiting?
Yes, NCT07332260 is actively recruiting participants. Contact the research team at mona.dixon.gundersen@unn.no for enrollment information.
Where is the NCT07332260 trial being conducted?
This trial is being conducted at Tromsø, Norway.
Who is sponsoring the NCT07332260 clinical trial?
NCT07332260 is sponsored by University Hospital of North Norway. The principal investigator is Mona Dixon Gundersen, MBChB, PhD at University Hospital of North Norway, Tromsø. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.